Literature DB >> 19710145

The Epstein-Barr virus protein kinase BGLF4 and the exonuclease BGLF5 have opposite effects on the regulation of viral protein production.

Regina Feederle1, Anja M Mehl-Lautscham, Helmut Bannert, Henri-Jacques Delecluse.   

Abstract

The Epstein-Barr virus BGLF4 and BGLF5 genes encode a protein kinase and an alkaline exonuclease, respectively. Both proteins were previously found to regulate multiple steps of virus replication, including lytic DNA replication and primary egress. However, while inactivation of BGLF4 led to the downregulation of several viral proteins, the absence of BGLF5 had the opposite effect. Using recombinant viruses that lack both viral enzymes, we confirm and extend these initial observations, e.g., by showing that both BGLF4 and BGLF5 are required for proper phosphorylation of the DNA polymerase processivity factor BMRF1. We further found that neither BGLF4 nor BGLF5 is required for baseline viral protein production. Complementation with BGLF5 downregulated mRNA levels and translation of numerous viral genes, though to various degrees, whereas BGLF4 had the opposite effect. BGLF4 and BGLF5 influences on viral expression were most pronounced for BFRF1 and BFLF2, two proteins essential for nuclear egress. For most viral genes studied, cotransfection of BGLF4 and BGLF5 had only a marginal influence on their expression patterns, showing that BGLF4 antagonizes BGLF5-mediated viral gene shutoff. To be able to exert its functions on viral gene expression, BGLF4 must be able to escape BGLF5's shutoff activities. Indeed, we found that BGLF5 stimulated the BGLF4 gene's transcription through an as yet uncharacterized molecular mechanism. The BGLF4/BGLF5 enzyme pair builds a regulatory loop that allows fine-tuning of virus protein production, which is required for efficient viral replication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710145      PMCID: PMC2772808          DOI: 10.1128/JVI.00525-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation.

Authors:  D G Wolf; C T Courcelle; M N Prichard; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

3.  Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.

Authors:  Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells.

Authors:  Gerry Shaw; Silas Morse; Miguel Ararat; Frank L Graham
Journal:  FASEB J       Date:  2002-04-10       Impact factor: 5.191

5.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.

Authors:  F Le Roux; A Sergeant; L Corbo
Journal:  J Gen Virol       Date:  1996-03       Impact factor: 3.891

8.  Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.

Authors:  H J Delecluse; T Hilsendegen; D Pich; R Zeidler; W Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

9.  The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress.

Authors:  Paula M Krosky; Moon-Chang Baek; Donald M Coen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency.

Authors:  M N Prichard; N Gao; S Jairath; G Mulamba; P Krosky; D M Coen; B O Parker; G S Pari
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

View more
  23 in total

1.  Gammaherpesvirus gene expression and DNA synthesis are facilitated by viral protein kinase and histone variant H2AX.

Authors:  Bryan C Mounce; Fei Chin Tsan; Lindsay Droit; Sarah Kohler; Justin M Reitsma; Lisa A Cirillo; Vera L Tarakanova
Journal:  Virology       Date:  2011-09-22       Impact factor: 3.616

2.  The "Bridge" in the Epstein-Barr virus alkaline exonuclease protein BGLF5 contributes to shutoff activity during productive infection.

Authors:  Daniëlle Horst; Wim P Burmeister; Ingrid G J Boer; Daphne van Leeuwen; Marlyse Buisson; Alexander E Gorbalenya; Emmanuel J H J Wiertz; Maaike E Ressing
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

Review 3.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

4.  Retrograde Regulation by the Viral Protein Kinase Epigenetically Sustains the Epstein-Barr Virus Latency-to-Lytic Switch To Augment Virus Production.

Authors:  Xiaofan Li; Sergei V Kozlov; Ayman El-Guindy; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

5.  Simian virus 40 T/t antigens and lamin A/C small interfering RNA rescue the phenotype of an Epstein-Barr virus protein kinase (BGLF4) mutant.

Authors:  Qiao Meng; Stacy R Hagemeier; Chad V Kuny; Robert F Kalejta; Shannon C Kenney
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  Key motifs in EBV (Epstein-Barr virus)-encoded protein kinase for phosphorylation activity and nuclear localization.

Authors:  Svetlana Gershburg; Leann Murphy; Manfred Marschall; Edward Gershburg
Journal:  Biochem J       Date:  2010-10-15       Impact factor: 3.857

7.  The DNase Activity of Kaposi's Sarcoma-Associated Herpesvirus SOX Protein Serves an Important Role in Viral Genome Processing during Lytic Replication.

Authors:  Timsy Uppal; Dylan Meyer; Andrea Agarwal; Subhash C Verma
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

8.  Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells.

Authors:  Xiaoping Sun; Jillian A Bristol; Satoko Iwahori; Stacy R Hagemeier; Qiao Meng; Elizabeth A Barlow; Joyce D Fingeroth; Vera L Tarakanova; Robert F Kalejta; Shannon C Kenney
Journal:  J Virol       Date:  2013-07-10       Impact factor: 5.103

9.  PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation.

Authors:  Farjana Saiada; Kun Zhang; Renfeng Li
Journal:  Cell Biosci       Date:  2021-07-08       Impact factor: 7.133

10.  Dual short upstream open reading frames control translation of a herpesviral polycistronic mRNA.

Authors:  Lisa M Kronstad; Kevin F Brulois; Jae U Jung; Britt A Glaunsinger
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.